Sunitinib achieved fast and sustained control of VIPoma symptoms

European Journal of Endocrinology

Volumn 172, Issue 1, 2015, Pages K1-K3

  De Mestier, Louis ^a   Walter, Thomas ^b   Brixi, Hedia ^a   Lombard Bohas, Catherine ^b   Cadiot, Guillaume ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; POTASSIUM; SUNITINIB; VASOACTIVE INTESTINAL POLYPEPTIDE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ABLATION THERAPY; ADULT; ARTICLE; CASE REPORT; CAUSE OF DEATH; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOKALEMIA; LIVER SURGERY; MALE; MIDDLE AGED; NUTRITIONAL DISORDER; OPTIMAL DRUG DOSE; PANCREAS SURGERY; PANCREATIC NEUROENDOCRINE TUMOR; POTASSIUM BLOOD LEVEL; RECURRENT DISEASE; SEPSIS; TIME TO TREATMENT; TREATMENT DURATION; VERNER MORRISON SYNDROME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; FATALITY; PANCREATIC NEOPLASMS; TIME; VIPOMA;

ADULT; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PYRROLES; TIME FACTORS; VIPOMA;

EID: 84920439114     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0682     Document Type: Article

References (12)

1. Jensen RT, Cadiot G, Brandi M.L., de Herder WW, Kaltsas G, Komminoth P, Scoazec J-Y, Salazar R, Sauvanet A & Kianmanesh R. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012 95 98-119. (doi:10.1159/000335591)
2. Smith SL, Branton SA, Avino A.J., Martin JK, Klinger PJ, Thompson GB, Grant CS & van Heerden JA. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998 124 1050-1055. (doi:10.1067/msy.1998.92005)
3. Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, Valle J., Metrakos P, Smith D, Vinik A et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 2011 364 501-513. (doi:10.1056/NEJMoa1003825)
4. Kulke MH, Bergsland EK & Yao JC. Glycemic control in patients with insulinoma treated with everolimus. New England Journal of Medicine 2009 360 195-197. (doi:10.1056/NEJMc0806740)
5. Bourcier ME, Sherrod A, DiGuardo M & Vinik AI. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. Journal of Clinical Endocrinology and Metabolism 2009 94 3157-3162. (doi:10.1210/jc.2009-0788)
6. Bernard V, Lombard-Bohas C, Taquet M-C, CaroliBosc F-X, Ruszniewski P, Niccoli P, Guimbaud R, Chougnet CN, Goichot B, Rohmer V et al. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. European Journal of Endocrinology 2013 168 665-674. (doi:10.1530/EJE-12-1101)
7. Bourcier ME & Vinik AI. Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). Pancreas 2013 42 348-352. (doi:10.1097/MPA. 0b013e31825c53fa)
8. Solcia E, Capella C, Riva C., Rindi G & Polak JM. The morphology and neuroendocrine profile of pancreatic epithelial VIPomas and extra-pancreatic, VIP-producing, neurogenic tumors. Annals of the New York Academy of Sciences 1988 527 508-517. (doi:10.1111/j.1749-6632.1988.tb27004.x)
9. Lebowitz-Amit R., Mete O, Asa S.L., Ezzat S & Joshua AM. Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review. Endocrine Practice 2014 20 145-150. (doi:10.4158/EP14093.CR)
10. Harty RF, Jain DK & McGuigan JE. Mechanisms of vasoactive intestinal peptide release in short-term culture of vasoactive intestinal peptide-producing tumor. Gastroenterology 1988 94 513-518. (doi:10.5555/uri:pii:0016508588904465)
11. Aita Y, Ishii KA, Saito Y, Ikeda T., Kawakami Y, Shimano H, Hara H & Takekoshi K. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-g-related pathways. American Journal of Physiology. Endocrinology and Metabolism 2012 303 1006-1014. (doi:10.1152/ajpendo.00156. 2012)
12. Modlin IM, Pavel M, Kidd M & Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Alimentary Pharmacology & Therapeutics 2010 31 169-188. (doi:10.1111/j.1365-2036.2009.04174.x)